Buscar
Mostrando ítems 11-17 de 17
Artículo
Off-target effects of bacillus Calmette–Guerin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19
(WILEY, 2022)
Background and objectives. Because of its beneficial off-target effects against non-mycobacterial infectious diseases, bacillus Calmette–Guerin (BCG) vaccination might be an accessible early intervention to boost ...
Artículo
Interplay between IncF plasmids and topoisomerase mutations conferring quinolone resistance in the Escherichia coli ST131 clone: stability and resistance evolution
(Springer, 2021-11-17)
The Escherichia coli ST131 H30-Rx subclone vehicles CTX-M-15 plasmids and mutations in gyrA and parC conferring multidrug resistance successfully in the clinical setting. The aim of this study was (1) to investigate the ...
Artículo
Effectiveness of fosfomycin trometamol as oral step-down therapy for bacteraemic urinary tract infections due to MDR Escherichia coli: a post hoc analysis of the FOREST randomized trial
(Oxford Academic, 2023)
Background Fosfomycin is a potentially attractive option as step-down therapy for bacteraemic urinary tract infections (BUTI), but available data are scarce. Our objective was to compare the effectiveness and safety of ...
Artículo
Clinical characteristics and outcome of bacteraemia caused by Enterobacter cloacae and Klebsiella aerogenes: more similarities than differences
(Elsevier, 2021)
Objectives The genus Enterobacter is a common cause of nosocomial infections. Historically, the most frequent Enterobacter species were those of Enterobacter cloacae complex and Enterobacter aerogenes. In 2019, E. ...
Artículo
Contribution of hypermutation to fosfomycin heteroresistance in Escherichia coli
(Oxford University Press, 2020)
Objectives: To explore the effect of combining defects in DNA repair systems with the presence of fosfomycin-resistant mechanisms to explain the mechanisms underlying fosfomycin heteroresistance phenotypes in Enterobacte ...
Artículo
Artículo
Temocillin versus meropenem for the targeted treatment of bacteraemia due to third-generation cephalosporin-resistant Enterobacterales (ASTARTÉ): protocol for a randomised, pragmatic trial
(BMJ Publishing Group, 2021)
Introduction: Alternatives to carbapenems are needed in the treatment of third-generation cephalosporin-resistant Enterobacterales (3GCR-E). Temocillin is a suitable candidate, but comparative randomised studies are lacking. ...